Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prozin is a topical antimicrobial cream containing 1.0% w/w silver sulfadiazine, developed and marketed by Regal Pharmaceuticals for the treatment of burns and wound infections. As a generic formulation of silver sulfadiazine, it functions through a dual mechanism: the release of silver ions provides broad-spectrum bactericidal and fungicidal activity by disrupting microbial cell walls and binding to DNA, while the sulfadiazine moiety acts as a competitive inhibitor of dihydropteroate synthase, an enzyme essential for bacterial folic acid synthesis. This combination of effects makes it highly effective in preventing and treating infections in second- and third-degree burns. The product is supplied as a white opaque cream in 15-gram tubes and is widely used in the East and Central African markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prozin.